Telomir Pharmaceuticals signs Linical agreements for breast cancer trial
TELO•Telomir Pharmaceuticals signed a master services agreement and clinical trial work order with Linical to advance its Telomir-Zn study. The FDA-cleared Phase 1/2 trial will evaluate the therapy in patients with advanced or metastatic triple-negative breast cancer, with clinical initiation targeted for the first quarter of 2027.




